Please assess the completion status of the following clinical trial:

Trial Title: Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adenocarcinoma of the prostate~* Progressive metastatic disease (i.e., positive bone scan or measurable disease) despite castrate levels of testosterone (either from orchiectomy or luteinizing hormone-releasing hormone \[LHRH\] agonist therapy)~  * Progressive disease after discontinuing hormonal therapy~ * Progressive disease is based on any of the following\*:~    * Transaxial imaging~   * Rise in prostate-specific antigen (PSA)~   * Radionuclide bone scan (must show new metastatic lesions)~* Nonmeasurable or measurable disease~  * For measurable disease, progression is defined by RECIST criteria~ * Positive bone scan and elevated PSA required for nonmeasurable disease~    * PSA evidence of progressive prostate cancer during or after first-line chemotherapy consists of a PSA level ≥ 2 ng/mL that has risen on ≥ 2 successive occasions ≥ 1 week apart~* Received ≥ 3 prior courses of paclitaxel- or docetaxel-based therapy, with disease progression documented during therapy or after cessation of therapy~  * No more than 1 prior chemotherapy regimen~ * Re-treatment with the same taxane-based regimen allowed~ * Changes in prior chemotherapy regimen (addition of other agents) for disease progression are considered 2 chemotherapy regimens, and are not allowed~* PSA ≥ 2 ng/mL~* Testosterone \< 50 ng/dL~  * Patients must continue primary androgen deprivation with LHRH analogue if they have not undergone orchiectomy~* No known active brain metastases~* ECOG performance status 0-2~* Life expectancy ≥ 12 weeks~* Creatinine ≤ 1.5 times upper limit of normal (ULN) OR creatinine clearance \> 40 mL/min~* ALT and AST \< 2.5 times ULN~* Granulocyte count ≥ 2,000/mm³~* Platelet count ≥ 100,000/mm³~* Bilirubin \< 1.5 times ULN~* Ejection fraction normal by MUGA scan or echocardiogram~* No significant cardiovascular disease, including any of the following:~  * Congestive heart failure (New York Heart Association class III-IV heart disease)~ * Active angina pectoris~ * Myocardial infarction within the past 6 months~* No serious infections or nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by study therapy~* No psychiatric illness or social situation that would preclude study compliance~* No pre-existing motor or sensory peripheral neuropathy \> grade 1~* No known prior severe hypersensitivity reactions to agents containing Cremophor® EL~* No currently active second malignancy other than nonmelanoma skin cancer~  * Patients are not considered to have a currently active malignancy if they have completed therapy and are considered to be at \< 30% risk of relapse~* Fertile patients must use effective contraception prior to, during, and for 3 months after completion of study treatment~* See Disease Characteristics~* No prior mitoxantrone hydrochloride, ixabepilone, or other epothilones~* At least 4 weeks since prior hormonal therapy (i.e., any dose of megestrol, finasteride, or any herbal product known to decrease PSA levels \[e.g., saw palmetto or PC-SPES\]) other than LHRH agonist or a stable dose of corticosteroids from a prior chemotherapy regimen~* More than 4 weeks since other prior systemic therapies for prostate cancer~* At least 4 weeks since prior radiation therapy~* More than 8 weeks since prior radiopharmaceuticals (e.g., strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium)~* No concurrent moderate to strong CYP3A4 inhibitors~* No concurrent prophylactic colony-stimulating factors~* No concurrent radiotherapy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (combination chemotherapy) (Type: EXPERIMENTAL): Patients receive mitoxantrone hydrochloride IV over 30 minutes and ixabepilone IV over 3 hours on day 1 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).